{
  "docId": "019de075-992f-724e-90ab-5f77d740e3ca",
  "docSlug": "2f355093e0d1610f6a0dd544c49160f7",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 33 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 33,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a clinical imaging case study (A-D) showing patient response over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-992f-724e-90ab-5f77d740e3ca/9",
  "deckHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca",
  "deckJsonHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca.json",
  "deckAnchorHref": "/decks/019de075-992f-724e-90ab-5f77d740e3ca#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.56,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Fusion acquired a Phase 2 IND (TATCIST trial) with plan to develop 225Ac-PSMA-I&T as a potential first to market",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdaf25f4-5692-442d-9c8c-12344c16e5c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.56,
        "y": 0.42
      },
      "kind": "image",
      "text": "Clinical imaging sequence A-D showing PSA levels decreasing from 294 to <0.1 ng/ml",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "360314d3-47a7-48c4-9b4a-98777db7b572",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.5,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "list",
      "text": "Fusion is uniquely positioned with our 225Ac supply and expertise to bring the first 225Ac-PSMA agent to market. Similar first-to-market opportunity to what Endocyte did with 177Lu-PSMA-617 (which became Pluvicto)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1479347c-bd6d-46f8-91c8-2cd49cfe6ef3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Clinical data is emerging showing documented activity of 225Ac-PSMA in patients who did not respond or progressed on or after 177Lu-PSMA. Creates opportunity to be a best-in-class therapy. 225Ac-PSMA-I&T has achieved clinical POC already in mCRPC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1efdcd2d-e309-4a94-bd44-0cdcdf2ab86c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.5,
        "x": 0.03,
        "y": 0.48
      },
      "kind": "list",
      "text": "Actinium supply barriers are preventing large scale studies and commercialization of the potentially superior alpha therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "577a5be7-b427-4657-a5cc-126f91a0470a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.56,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Kratochwil et al. (2016) J. Nucl. Med. 57:1941-1944",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65c5fb68-4c96-43e8-8e72-ebf0c0069600",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-2265: Fusion’s Phase 2 Actinium-Based PSMA Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14a03aa8-ab69-42f8-9387-f70ffb86e239",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "4a11ac64-18f5-48e0-b1ff-659c50aac756",
      "evidence": "Creates opportunity to be a best-in-class therapy.",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "ce3e4bc2-9718-442b-afea-9dde4f69ae46",
      "evidence": "Creates opportunity to be a best-in-class therapy.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "first-to-market",
      "slug": null,
      "matchId": "68349a1b-09a8-4b05-b46c-348889a60b48",
      "evidence": "Mentions first-to-market opportunity and competitive positioning",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "f986bb4f-9181-47b0-a7be-a48832a68309",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Multiple investigator sponsored studies support potential of 225Ac-PSMA",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "025171a9-8d84-47fd-8ab7-652a56c1e9fb",
      "evidence": "Multiple investigator sponsored studies support potential of 225Ac-PSMA",
      "position": 1,
      "objective": "Highlighting the potential of 225Ac-PSMA as a quick win and big bet",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}